Neurobiological Correlates of Psilocybin Response in Depression

Saleha Qasim, MBBS; Zaofashan Zaheer, FSc; Muhammad Youshay Jawad, MBBS; Mujeeb U. Shad, MD, MSCS

Prim Care Companion CNS Disord 2023;25(3):22r03419

ABSTRACT

Objective: To synthesize the neurobiological basis of brain-resetting effects of psilocybin and identify neuroimaging correlates of psilocybin response in depressed patients.

Data Sources: MEDLINE(R), Embase, APA PsycINFO, Cochrane, and CINAHL were systematically searched on June 3, 2022, with no date restrictions using the following string: (psilocybin) AND (psychedelics) AND (MRI) OR (fMRI)) OR (PET)) OR (SPECT)) OR (imaging)) OR (neuroimaging)).

Study Selection: After duplicates were removed from 946 studies, 391 studies remained, of which 8 qualified for full-text analysis, but only 5 fulfilled the eligibility criteria of randomized, double-blind, or open-label neuroimaging study with psilocybin treatment in depressed patients.

Data Extraction: The Covidence platform was used for deduplication and bias assessment. The a priori data points included concomitant psychological intervention, modality of neuroimaging technique, changes in depression scores, brain functional changes, and association between functional and psilocybin response. Assessment bias was assessed with the standard risk of bias tool for randomized controlled trials and the tool for risk of bias in nonrandomized studies of interventions.

Results: Four studies were open-label, and one was a combined open-label and randomized controlled trial using functional magnetic resonance imaging. Psilocybin-assisted psychotherapy was administered in 3 studies, 1 in refractory and 2 in nonrefractory patients. The remaining 2 studies were in refractory patients. The transient increase in psilocybin-induced global connectivity in major neural tracts and specific areas of brain activation was associated with antidepressant response.

Conclusions: Transient functional brain changes with psilocybin therapy resemble the “brain reset” phenomenon and may serve as the putative predictors of psilocybin antidepressant response.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (49)

McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015;20(suppl 1):17–30, quiz 31. PubMed CrossRef
Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370–377. PubMed
Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(suppl 6):16–22. PubMed
Goodwin GM, Price J, De Bodinat C, et al. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35. PubMed CrossRef
Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28(2):121–141. PubMed
Seligman PJ, Anguiano RH, Felix T, et al. Managing the risks of medicines: an examination of FDA’s application of criteria for requiring a REMS. Ther Innov Regul Sci. 2019;53(4):542–548. PubMed CrossRef
Heifets BD, Bentzley BS, Williams N, et al. Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al. Mol Psychiatry. 2021;26(11):6104–6106. PubMed CrossRef
Williams NR, Heifets BD, Bentzley BS, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24(12):1779–1786. PubMed CrossRef
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42(11):2105–2113. PubMed CrossRef
Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020;411:116715. PubMed CrossRef
Vargas AS, Luís Â, Barroso M, et al. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. Biomedicines. 2020;8(9):331. PubMed CrossRef
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. PubMed CrossRef
Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151–158. PubMed CrossRef
Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844–851. PubMed CrossRef
Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. PubMed CrossRef
Sellers EM. Psilocybin: Good Trip or Bad Trip. Clin Pharmacol Ther. 2017;102(4):580–584. PubMed CrossRef
Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. PubMed CrossRef
Bienemann B, Ruschel NS, Campos ML, et al. Self-reported negative outcomes of psilocybin users: a quantitative textual analysis. PLoS One. 2020;15(2):e0229067. PubMed CrossRef
Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268–1278. PubMed CrossRef
Krebs TS, Johansen PO. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972. PubMed CrossRef
Johansen PO, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270–279. PubMed CrossRef
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. PubMed CrossRef
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–799. PubMed CrossRef
Roseman L, Demetriou L, Wall MB, et al. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 2018;142:263–269. PubMed CrossRef
Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187. PubMed CrossRef
Mertens LJ, Wall MB, Roseman L, et al. Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020;34(2):167–180. PubMed CrossRef
Doss MK, Považan M, Rosenberg MD, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11(1):574. PubMed CrossRef
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. PubMed CrossRef
Goodman ZT, Bainter SA, Kornfeld S, et al. Whole-brain functional dynamics track depressive symptom severity. Cereb Cortex. 2021;31(11):4867–4876. PubMed CrossRef
Hamilton JP, Furman DJ, Chang C, et al. Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol Psychiatry. 2011;70(4):327–333. PubMed CrossRef
Andrews-Hanna JR, Smallwood J, Spreng RN. The default network and self-generated thought: component processes, dynamic control, and clinical relevance. Ann N Y Acad Sci. 2014;1316(1):29–52. PubMed CrossRef
Lyons T, Carhart-Harris RL. More realistic forecasting of future life events after psilocybin for treatment-resistant depression. Front Psychol. 2018;9:1721. PubMed CrossRef
Kim C, Cilles SE, Johnson NF, et al. Domain general and domain preferential brain regions associated with different types of task switching: a meta-analysis. Hum Brain Mapp. 2012;33(1):130–142. PubMed CrossRef
Turnbull A, Karapanagiotidis T, Wang HT, et al. Reductions in task positive neural systems occur with the passage of time and are associated with changes in ongoing thought. Sci Rep. 2020;10(1):9912. PubMed CrossRef
Berman MG, Peltier S, Nee DE, et al. Depression, rumination and the default network. Soc Cogn Affect Neurosci. 2011;6(5):548–555. PubMed CrossRef
Hamilton JP, Farmer M, Fogelman P, et al. Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. Biol Psychiatry. 2015;78(4):224–230. PubMed CrossRef
Mulders PC, van Eijndhoven PF, Pluijmen J, et al. Default mode network coherence in treatment-resistant major depressive disorder during electroconvulsive therapy. J Affect Disord. 2016;205:130–137. PubMed CrossRef
Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016;113(17):4853–4858. PubMed CrossRef
Palhano-Fontes F, Andrade KC, Tofoli LF, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One. 2015;10(2):e0118143. PubMed CrossRef
Smigielski L, Scheidegger M, Kometer M, et al. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. 2019;196:207–215. PubMed CrossRef
Carhart-Harris RL, Erritzoe D, Haijen E, et al. Psychedelics and connectedness. Psychopharmacology (Berl). 2018;235(2):547–550. PubMed CrossRef
Pang Y, Wei Q, Zhao S, et al. Enhanced default mode network functional connectivity links with electroconvulsive therapy response in major depressive disorder. J Affect Disord. 2022;306:47–54. PubMed CrossRef
Lewis CR, Preller KH, Kraehenmann R, et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. 2017;159:70–78. PubMed CrossRef
Vollenweider FX, Leenders KL, Oye I, et al. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7(1):25–38. PubMed CrossRef
Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138–2143. PubMed CrossRef
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902. PubMed CrossRef
Beliveau V, Ozenne B, Strother S, et al. The structure of the serotonin system: a PET imaging study. Neuroimage. 2020;205:116240. PubMed CrossRef
Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol. 1994;9(suppl 3):13–19. PubMed CrossRef